Dino A Rossi sold $8.2M of KRYS
director at Krystal Biotech, Inc.. 25,000 shares at an average of $329.12, traded Aug 14, 2026, filed Aug 14, 2026.
Score components
- +15RoleDirector
- +25Trade size$8.2M at market
- +10Share of holdings soldSold 33% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001209059-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | GGift Common Stock | -3,691 | $0.00 | $0 | 75,000 | Aug 14, 2026 |
| Aug 14, 2026 | SOpen-market sale Common Stock | -341 | $325.60 | $111k | 74,659 | Aug 14, 2026 |
| Aug 14, 2026 | SOpen-market sale Common Stock | -2,287 | $326.60 | $747k | 72,372 | Aug 14, 2026 |
| Aug 14, 2026 | SOpen-market sale Common Stock | -5,226 | $327.39 | $1.7M | 67,146 | Aug 14, 2026 |
| Aug 14, 2026 | SOpen-market sale Common Stock | -1,687 | $328.52 | $554k | 65,459 | Aug 14, 2026 |
| Aug 14, 2026 | SOpen-market sale Common Stock | -7,428 | $329.60 | $2.4M | 58,031 | Aug 14, 2026 |
| Aug 14, 2026 | SOpen-market sale Common Stock | -4,896 | $330.36 | $1.6M | 53,135 | Aug 14, 2026 |
| Aug 14, 2026 | SOpen-market sale Common Stock | -3,095 | $331.43 | $1.0M | 50,040 | Aug 14, 2026 |
| Aug 14, 2026 | SOpen-market sale Common Stock | -40 | $333.23 | $13k | 50,000 | Aug 14, 2026 |
Related signals
Other insiders at Krystal Biotech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $9.0M 25,000 shares | -2% | |
| 33Weak | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $9.0M 25,000 shares | -2% | |
| 15Weak | Krystal Biotech, Inc. | John Charles Thomas EVP, General Counsel | $347k 1,000 shares | -100% | |
| 45Moderate | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $7.7M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $7.7M 25,000 shares | -2% | |
| 42Moderate | Krystal Biotech, Inc. | John Charles Thomas EVP, General Counsel | $194k 642 shares | -100% | |
| 45Moderate | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $6.6M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $6.6M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Daniel Janney director | $3.3M 11,803 shares | -14% | |
| 7Weak | Krystal Biotech, Inc. | Kathryn Romano Chief Accounting Officer | $201k 750 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.